Sign inJoin waitlistJoin the waitlist

Elie Dib

Associate Program Director · Trinity Health Ann Arbor Hospital

Credentials: · · · · · · · · ·

History

Trinity Health Ann Arbor Hospital
Present
Johns Hopkins University
Present

Hematology and Medical Oncology
University of Rochester Medicine
2003–2006
Internal Medicine
Staten Island University Hospital
2000–2003
Lebanese University
1999–2000
Johns Hopkins University
Harvard Medical School
LEBANESE UNIV SCHOOL OF MED FAC OF MED SCIENCES, BEIRUT
1995–1999

Research

Polypharmacy, Potentially Inappropriate Medications, and Drug-Drug Interactions in Vulnerable Older Adults With Advanced Cancer Initiating Cancer Treatment
The Oncologist · 2022 · 74 citations
Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
JCO Precision Oncology · 2020 · 64 citations
Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell…
Investigational New Drugs · 2022 · 51 citations

Richard Schilsky
7 papers
EP
Evan Pisick
4 papers
Supriya Mohile
4 papers
Anu Gaba
3 papers
Eugene Ahn
3 papers
Herbert Duvivier
3 papers
NV
Nicholas Vogelzang
3 papers
Olatunji Alese
3 papers
Ramya Thota
3 papers
Steven Powell
3 papers
TC
Timothy Cannon
3 papers
Adedayo Onitilo
2 papers

Grants

Research Capacity Building by a Clinician Scientist Within the Michigan Cancer Research Consortium- National Community Oncology Research Program
National Cancer Institute · R50
Contact PI · $339.6K · Saint Joseph Mercy Health System
2024–2029

Clinical trials

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2029
Family Communications After Genetic Testing
Site PI · Recruiting
Alliance for Clinical Trials in Oncology
2026–2032
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2025–2029
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037